RE:RE:Merck shortage of BCGIn light of the fact that the current standard of care cannot be administered properly due to the shortage of BCG, one could argue that TLT should be considered for approval for more than just BCG unresponsive. Given our safety profile and our impressive results to date, I cannot see how we don't get approved. I will lose what little faith I have in the beauracracy that is the FDA if we don't.